Literature DB >> 2421877

Effects of cytotoxicity of 2-chloro-2'-deoxyadenosine and 2-bromo-2'-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics.

M C Huang, R A Ashmun, T L Avery, M Kuehl, R L Blakley.   

Abstract

The cytotoxic effects of the adenosine deaminase resistant analogues 2-bromo-2'-deoxyadenosine (2-BrdAdo) and 2-chloro-2'-deoxyadenosine (2-CldAdo) have been compared with those of deoxyadenosine (dAdo). Like 2-CldAdo, 2-BrdAdo is highly effective in inhibiting the growth of many T-lymphoblastoid, B-lymphoblastoid, and myeloid cell lines in culture. Concentrations required to inhibit growth of CCRF-CEM human T-lymphoblastoid cells by 50% (IC50) are: 2-CldAdo, 0.045 microM; 2-BrdAdo, 0.068 microM; dAdo, 0.9 microM in the presence of 5 microM erythro-9-(2-hydroxy-3-nonyl)adenine. Like dAdo, 2-BrdAdo causes a much greater decrease in DNA synthesis than in RNA and protein synthesis. For each of the nucleosides the concentration required to cause 50% inhibition of DNA synthesis (as measured by thymidine incorporation) in an 18-h exposure is very similar to the IC50 for growth and to the concentration required to decrease viability (clonogenicity) over 18 h by 50% (EC50). A fraction of CCRF-CEM cells (approximately equal to 30%) is resistant to killing by exposure to 2-BrdAdo or 2-CldAdo for 4 h at concentrations 100 times the EC50, but 3% of cells are resistant to exposure for 4 h to a concentration of dAdo 3 times the EC50. Each of the three nucleosides causes accumulation of cells in S phase, the accumulation becoming more marked with longer periods of exposure and with higher concentrations of nucleoside. During exposures for 18-24 h at a concentration of nucleoside near the EC50 most cells accumulate in S, with most in early S, whereas exposure to concentrations greater than EC95 accumulates cells at the G1/S border. This suggests that loss of viability is associated with a blockade of some process specifically occurring at the initiation of S phase. At an optimum dosage schedule, 2-BrdAdo and 2-CldAdo have similar therapeutic effects against L1210 in vivo, both producing over 99% cell kill, but the optimum dosage of 2-CldAdo is lower.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421877

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Effects of 2-chloroadenine substitution in DNA on restriction endonuclease cleavage reactions.

Authors:  P Hentosh; J C McCastlain
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

2.  Toxicity and metabolism of 3'-deoxyadenosine N1-oxide in mice and Ehrlich ascites tumor cells.

Authors:  K R Svendsen; K Overgaard-Hansen; S Frederiksen; S A Engelholm; N T Pedersen; L L Vindeløv
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine.

Authors:  R B Gartenhaus; P Wang; M Hoffman; D Janson; K R Rai
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

Review 4.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

5.  Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells.

Authors:  L B Pemble; M G Lihou; R L Blakley; G P Jamieson; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  2-Chloro-2'-deoxyadenosine monophosphate residues in DNA enhance susceptibility to 3'-->5' exonucleases.

Authors:  P Hentosh; P Grippo
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

7.  The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer.

Authors:  Yifeng He; Qiujing Zhu; Mo Chen; Qihong Huang; Wenjing Wang; Qing Li; Yuting Huang; Wen Di
Journal:  Oncotarget       Date:  2016-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.